Navigation Links
AnaptysBio Develops Novel Antibody Scaffold With Extreme Thermostability
Date:12/4/2012

SAN DIEGO, Dec. 4, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the publication of a novel full-length antibody scaffold, applicable to the development of highly thermostable antibodies for therapeutic and diagnostic applications, in the journal of Protein Engineering, Design & Selection (PEDS).  

(Logo:  http://photos.prnewswire.com/prnh/20111205/SF16052LOGO)

Entitled "An integrated approach to extreme thermostabilization and affinity maturation of an antibody", Dr. David J. King, chief scientific officer of AnaptysBio, and his team describe a novel IgG scaffold that maintains high binding affinity to its target antigen despite exposure to high temperature conditions for extended periods.   Accelerated stability data indicates that antibodies generated using this technology would remain stable at room temperature for several years.

To date, this novel approach has been successfully utilized by AnaptysBio to generate highly stable antibodies against multiple antigens.  As demonstrated in the aforementioned publication, existing antibodies with poor stability parameters can be effectively transformed by AnaptysBio's SHM-XEL platform to confer high thermal stability, while simultaneously improving binding affinity.   In addition, AnaptysBio has designed diverse library repertoires that permit de novo discovery of high thermostability antibodies in the context of its proprietary SHM-XEL platform. 

"To our knowledge, this publication describes the most stable full-length antibody reported to date," said Hamza Suria, president & chief executive officer of AnaptysBio. "Our ability to generate antibodies with extended room temperature thermostability provides a significant commercial advantage to future antibody-based therapeutic and diagnostic products.  Enhanced thermostability would reduce, or even eliminate, cold chain dependency during production, shipping and storage of antibody products.  These advantages may be particularly useful in developing countries, where the availability of antibody products is often constrained by dependency on refrigeration systems."

About AnaptysBio

Founded in 2005, AnaptysBio, Inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (SHM) for antibody discovery and optimization. AnaptysBio's proprietary SHM-XEL platform, which couples fully human antibody libraries with in vitro somatic hypermutation (SHM) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies.  By harnessing the natural mechanism of antibody maturation under controlled conditions, SHM-XEL allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability.   AnaptysBio has established broad intellectual property around the use of SHM and is currently building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders and antibody-drug conjugate applications. The Company has previously announced pharma partnerships with Merck, Roche, Novartis, Celgene and Gilead.  Major investors in AnaptysBio include Alloy Ventures, Avalon Ventures, Frazier Healthcare Ventures and Novo A/S.  For more information, visit www.anaptysbio.com.

 


'/>"/>
SOURCE AnaptysBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Anaptysbio Expands Leadership Team With Addition Of Dr. Andrew J. Mcknight
2. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
3. Millennium Surgical Corp. Develops Online Sterilization Resource Center
4. Softway Solutions Develops Award-Winning Health App for Texas Heart Institute
5. World Renowned Inventor, Donald Spector, Develops Patent For Wireless Electric Acupuncture Patches
6. China Health Resource Develops Revolutionary Migraine Medication
7. Synapse Develops Technology for Innovative Asthma Management Device
8. Life Technologies Develops Simplified SAME-DAY STEC Solution for Detecting Multiple Strains of E. coli in Ground Beef
9. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
10. AVT Develops New Line of Automated Stores For the Healthcare Industry
11. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Maxor National Pharmacy Services, LLC ("Maxor"), ... has named Leah Bailey as General Counsel.  Bailey ... the company. With more than 13 years ... years focused on health care, Bailey joins the Maxor ... Prime, Bailey advised the PBM, Specialty, and Mail Order ...
(Date:3/29/2017)... 29, 2017 Varian Medical Systems (NYSE: ... the second quarter of fiscal year 2017 following the close ... release will be followed by a teleconference available to all ... a link to the conference call webcast will be available ... the teleconference call and replay: ...
(Date:3/29/2017)...  Spiral Therapeutics, Inc. today announced the signature ... for the worldwide exclusive rights to Bionure,s lead ... of otolaryngology for aggregate payments of up to ... provides Spiral with the option to license two ... Under the terms of the agreement, Spiral will ...
Breaking Medicine Technology:
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... office buildings (MOBs) and other outpatient facilities, and who are the most active ... at those questions, Revista and Healthcare Real Estate Insights (HREI) found that outpatient ...
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
(Date:3/29/2017)... ... ... The Wharton School of the University of Pennsylvania is pleased to announce that ... gift to establish the Ken Moelis and Julie Taffet Moelis Advance Access Program ... for highly-qualified Penn undergraduates whose academic and career interests expand traditional notions of business ...
(Date:3/28/2017)... ... ... many women, getting birth control isn’t as easy as it should be. In fact, millions ... a health care facility or a pharmacy within 60 minutes of where they live. This ... many who are faced with health or personal issues that leave them homebound. To help ...
(Date:3/28/2017)... ... March 29, 2017 , ... ... pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March ... common questions regarding thyroid function. , Dr. Izabella Wentz is a licensed ...
Breaking Medicine News(10 mins):